Bottom line
FBTAX vs RYOIX: the short answer
FBTAX (Fidelity Advisor Biotechnology Fund) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 47% by weight.
FBTAX is cheaper at 0.94% vs 1.38% — a difference of $44 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs +4.0% for RYOIX (reporting dates differ).
Updated Nov 19, 2026
FBTAX vs RYOIX side by side
| FBTAX | RYOIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.94% | 1.38% |
| Annual cost per $10k | $94 | $138 |
| 10-yr cost on $10k (prospectus) | $1,663 | $1,709 |
| Max front load | — | — |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +31.5% | +30.7% |
| 5-yr return (annualized) | +6.4% | +4.0% |
| 10-yr return (annualized) | +7.7% | +5.9% |
| Best quarter | +30.3% | +28.3% |
| Worst quarter | −27.8% | −22.5% |
| Net assets (fund) | $2.2B | $136.8M |
| Number of holdings | 129 | 74 |
| Portfolio turnover | 54% | 75% |
| Returns as of | Sep 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBTAX | RYOIX | Difference |
|---|---|---|---|
| 2025 | +39.6% | +30.7% | +8.8% |
| 2024 | +5.3% | −0.7% | +6.1% |
| 2023 | +10.7% | +6.1% | +4.6% |
| 2022 | −8.0% | −13.1% | +5.1% |
| 2021 | −3.6% | +1.8% | −5.4% |
| 2020 | +32.2% | +22.1% | +10.1% |
| 2019 | +25.7% | +25.0% | +0.7% |
| 2018 | −3.8% | −9.0% | +5.2% |
| 2017 | +25.8% | +29.7% | −3.9% |
| 2016 | −23.6% | −19.5% | −4.1% |
Source: Fund prospectus bar charts
Holdings overlap
11 of FBTAX's top 25 holdings also appear in RYOIX's top 25.
| Holding | FBTAX | RYOIX |
|---|---|---|
| Abbvie Inc | 14.71% | 8.17% |
| Gilead Sciences Inc | 5.70% | 4.49% |
| Alnylam Pharmaceuticals Inc | 3.62% | 2.36% |
| Insmed Inc | 3.05% | 1.79% |
| Revolution Medicines Inc | 3.00% | 2.48% |
| Argenx Se | 3.00% | 1.48% |
| Biogen Inc | 2.71% | 2.13% |
| Amgen Inc | 2.37% | 5.05% |
| Moderna Inc | 1.60% | 2.15% |
| Natera Inc | 1.43% | 2.12% |
| Vertex Pharmaceuticals Inc | 1.39% | 4.32% |
Source: SEC Form N-PORT
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between FBTAX and RYOIX?
Which is cheaper, FBTAX or RYOIX?
Should I own both FBTAX and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.